HDP-101, a novel antibody-drug conjugate, targets BCMA with a synthetic amanitin payload that causes tumor cell death.

Another breakthrough has been with ADCs in combination with other treatments, such as an immunotherapy that inhibits the ...

Lifordi Immunotherapeutics, Inc., today announced that it has received the Endpoints 11 Award from Endpoints News, an honor ...

Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.

It represents 82% of the ADC pipeline in major APAC markets. A surge in antibody-drug conjugates (ADCs) is driving China to ...

First Drug Is Expected To Be Available In Market By 2029 Says Kuick In Its ReportDelhi, Sept. 17, 2024 (GLOBE NEWSWIRE) -- ...

Treatment with the antibody-drug conjugate TORL-1-23 was safe and tolerable in heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer.

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...

The drug helped patients live significantly longer without their cancer progressing, compared with patients who were treated ...

Phase I data presented at ESMO suggested that TORL-1-23 may have particularly strong activity in CLDN-positive advanced ...

A first-in-human phase I study of TORL-1-23, an antibody drug conjugate (ADC) targeting the protein claudin 6, showed good ...